UNLIMITED TURBO BULL - ASTRAZENECA | Real-time Euronext Paris 07:04:44 2024-06-04 am EDT | ||
| 2.605 EUR | +0.97% |
|
| Current month | +10.49% | ||
| 1 month | +10.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 2.605 | +0.97% |
| 24-06-03 | 2.58 | +10.49% |
| 24-05-31 | 2.335 | +4.71% |
| 24-05-30 | 2.23 | +6.44% |
| 24-05-29 | 2.095 | -5.20% |
Real-time Euronext Paris
Last update June 04, 2024 at 07:04 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| 8V39S | |
| ISIN | DE000SW9DHQ7 |
| Date issued | 2024-04-23 |
| Strike | 10,198 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.705 € |
|---|---|
| Lowest since issue | 1.365 € |
| Spread | 0.01 € |
| Spread % | 0.38% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.9
USD
Average target price
172.1
USD
Spread / Average Target
+8.96%
- Stock Market
- Certificates
- 8V39S Certificat
